{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:49:58Z","timestamp":1787942998562,"version":"build-2784847793"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"am","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.dmpk.2024.101024","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T12:11:22Z","timestamp":1717157482000},"page":"101024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Population pharmacokinetic analysis of sirolimus in Japanese pediatric and adult subjects receiving tablet or granule formulations"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6571-5651","authenticated-orcid":false,"given":"Taichi","family":"Miyazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6272-5638","authenticated-orcid":false,"given":"Shiho","family":"Yasue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2228-1272","authenticated-orcid":false,"given":"Ryuta","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototoshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8488-4752","authenticated-orcid":false,"given":"Takanobu","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8886-2515","authenticated-orcid":false,"given":"Shigehisa","family":"Fumino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naonori","family":"Kawakubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Tajiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Sanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2552-0240","authenticated-orcid":false,"given":"Mayumi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8790-906X","authenticated-orcid":false,"given":"Kashyap","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2024.101024_bib1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.reth.2018.12.001","article-title":"Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: a study protocol for an open-label, single-arm, multicenter, prospective study (SILA)","volume":"10","author":"Ozeki","year":"2019","journal-title":"Regen Ther"},{"issue":"2","key":"10.1016\/j.dmpk.2024.101024_bib5","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3257","article-title":"Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies","volume":"137","author":"Adams","year":"2016","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.dmpk.2024.101024_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1034\/j.1399-0012.2000.140201.x","article-title":"Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity","volume":"14","author":"Kahan","year":"2000","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1016\/j.dmpk.2024.101024_bib7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/FTD.0b013e318286dd3f","article-title":"Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1","volume":"35","author":"Scott","year":"2013","journal-title":"Ther Drug Monit"},{"issue":"Suppl 3","key":"10.1016\/j.dmpk.2024.101024_bib8","article-title":"How we approach the use of sirolimus and new agents: medical therapy to treat vascular anomalies","volume":"69","author":"Shimano","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101024_bib9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jvs.2019.06.217","article-title":"Efficacy and safety of sirolimus in the treatment of vascular anomalies: a systematic review","volume":"71","author":"Freixo","year":"2020","journal-title":"J Vasc Surg"},{"issue":"12","key":"10.1016\/j.dmpk.2024.101024_bib10","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology--drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.dmpk.2024.101024_bib11","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1002\/psp4.17","article-title":"Development of a pediatric physiologically based pharmacokinetic model for sirolimus: applying principles of growth and maturation in neonates and infants","volume":"4","author":"Emoto","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"10.1016\/j.dmpk.2024.101024_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26470","article-title":"Developmental pharmacokinetics of sirolimus: implications for precision dosing in neonates and infants with complicated vascular anomalies","volume":"64","author":"Mizuno","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.dmpk.2024.101024_bib13","article-title":"Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies","volume":"109s","author":"Mizuno","year":"2017","journal-title":"Eur J Pharmaceut Sci"},{"issue":"11","key":"10.1016\/j.dmpk.2024.101024_bib14","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1513\/AnnalsATS.201605-335OC","article-title":"Efficacy and safety of long-term sirolimus therapy for asian patients with lymphangioleiomyomatosis","volume":"13","author":"Takada","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.dmpk.2024.101024_bib15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/acn3.51505","article-title":"Sirolimus for epileptic seizures associated with focal cortical dysplasia type II","volume":"9","author":"Kato","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"10.1016\/j.dmpk.2024.101024_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12161","article-title":"Model evaluation of continuous data pharmacometric models: metrics and graphics","volume":"6","author":"Nguyen","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101024_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","article-title":"Diagnosing model diagnostics","volume":"82","author":"Karlsson","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2024.101024_bib18","author":"Karlsson"},{"issue":"2","key":"10.1016\/j.dmpk.2024.101024_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.dmpk.2024.101024_bib21","unstructured":"Japan Ministry of Health L, and Welfare. National health and nutrition survey\/heisei 30 national health and nutrition. Table 14, Surveyor 2018. https:\/\/www.e-stat.go.jp\/stat-search\/files?page=1&query=%E8%BA%AB%E9%95%B7%E3%83%BB%E4%BD%93%E9%87%8D%E3%81%AE%E5%B9%B3%E5%9D%87%E5%80%A4%E5%8F%8A%E3%81%B3%E6%A8%99%E6%BA%96%E5%81%8F%E5%B7%AE%20&sort=year_month%20desc&layout=dataset&stat_infid=000031934466&metadata=1&data=1 [Accessed 22 October 2022]."},{"issue":"220","key":"10.1016\/j.dmpk.2024.101024_bib22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/adc.41.220.681","article-title":"A simple empirical formula for calculating approximate surface area in children","volume":"41","author":"Costeff","year":"1966","journal-title":"Arch Dis Child"},{"issue":"4","key":"10.1016\/j.dmpk.2024.101024_bib23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.bbmt.2012.12.015","article-title":"Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation","volume":"19","author":"Goyal","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.dmpk.2024.101024_bib24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/FTD.0000000000000313","article-title":"Therapeutic drug monitoring, electronic health records, and pharmacokinetic modeling to evaluate sirolimus drug exposure-response relationships in renal transplant patients","volume":"38","author":"Zimmerman","year":"2016","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.dmpk.2024.101024_bib25","first-page":"2412","article-title":"Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: a retrospective study","volume":"18","author":"Wang","year":"2019","journal-title":"Oncol Lett"},{"issue":"8","key":"10.1016\/j.dmpk.2024.101024_bib26","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jcph.2033","article-title":"Population pharmacokinetic analysis and dosing optimization of sirolimus in children with tuberous sclerosis complex","volume":"62","author":"Li","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmpk.2024.101024_bib27","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0009-9236(97)90192-2","article-title":"Population pharmacokinetics of sirolimus in kidney transplant patients","volume":"61","author":"Ferron","year":"1997","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmpk.2024.101024_bib28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2125.2005.02533.x","article-title":"A Bayesian approach for population pharmacokinetic modelling of sirolimus","volume":"62","author":"Dansirikul","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.dmpk.2024.101024_bib29","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200645110-00007","article-title":"Sirolimus population pharmacokinetic\/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients","volume":"45","author":"Djebli","year":"2006","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmpk.2024.101024_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0009-9120(98)00048-4","article-title":"Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update","volume":"31","author":"Trepanier","year":"1998","journal-title":"Clin Biochem"},{"issue":"8","key":"10.1016\/j.dmpk.2024.101024_bib31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/00003088-200140080-00002","article-title":"Clinical pharmacokinetics of sirolimus","volume":"40","author":"Mahalati","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.dmpk.2024.101024_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2012.18","article-title":"Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancer","volume":"1","author":"Wu","year":"2012","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436724000302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436724000302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:51:02Z","timestamp":1762368662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436724000302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":28,"alternative-id":["S1347436724000302"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2024.101024","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetic analysis of sirolimus in Japanese pediatric and adult subjects receiving tablet or granule formulations","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2024.101024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd on behalf of The Japanese Society for the Study of Xenobiotics.","name":"copyright","label":"Copyright"}],"article-number":"101024"}}